Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions. Read More
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is an undervalued pharmaceutical stock with strong profitability, a high dividend yield, and attractive valuation metrics, making it a candidate for value investors.
The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliance’s patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily and this program will provide a simple and transparent way to access it.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY)
fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other headwinds. Ahead of its second-quarter earnings report, UBS reiterated its "Neutral" rating on the stock. The firm's note pointed to several challenges, including an expected $1.5 billion expense for in-process research and development (IPR&D) related to a collaboration with BioNTech. This charge is anticipated to reduce the company's earnings per share (EPS) by approximately $0.60. The report also touched on broader investor concerns, such as the impact of Medicare's Part D redesign on several of the company's high-priced drugs and the looming patent expirations for key products. These factors contribute to a more cautious outlook on the pharmaceutical giant's near-term profitability and growth prospects.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with Opdivo.
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.
